[Beta 2 agonists between the FDA, Cochrane and reality]

Pneumologia. 2009 Jan-Mar;58(1):4-5, 7.
[Article in Romanian]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Administration, Inhalation
  • Adrenergic beta-Agonists / adverse effects
  • Adrenergic beta-Agonists / therapeutic use*
  • Albuterol / analogs & derivatives
  • Albuterol / therapeutic use
  • Databases, Factual*
  • Drug Therapy, Combination
  • Ethanolamines / therapeutic use
  • Evidence-Based Medicine
  • Formoterol Fumarate
  • Glucocorticoids / therapeutic use
  • Humans
  • Lung Diseases, Obstructive / drug therapy*
  • Meta-Analysis as Topic
  • Randomized Controlled Trials as Topic
  • Salmeterol Xinafoate
  • United States
  • United States Food and Drug Administration*

Substances

  • Adrenergic beta-Agonists
  • Ethanolamines
  • Glucocorticoids
  • Salmeterol Xinafoate
  • Albuterol
  • Formoterol Fumarate